Clinical Trial Update: GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase II open-label study of AFM13 in relapsed or refractory Hodgkin lymphoma has completed recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• AFM13

Snippet

Sponsor: University of Cologne | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED